For example, the development of effective migraine therapeutics targeting CGRPα or its receptor confirm the important role this peptide plays in headache (De Matteis et al., 2020; Tso and Goadsby, 2017), and new efferent functions for both CGRPα and Substance P are regularly being uncovered (Brain, 1997; Caceres et al., 2009; Perner et al., 2020; Pinho-Ribeiro et al., 2016; Wilhelms et al., 2018; Yang et al., 2022). Here, TAC1 is linked to migraine disorder.